東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

A New Oncogenic Function of the Glyc...

Gramyk, Tobin.

FindBook

Google Book

Amazon

博客來

A New Oncogenic Function of the Glycolytic Enzyme Lactate Dehydrogenase-A in Small Cell Lung Cancer.

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	A New Oncogenic Function of the Glycolytic Enzyme Lactate Dehydrogenase-A in Small Cell Lung Cancer./
作者:	Gramyk, Tobin.
出版者:	Ann Arbor : ProQuest Dissertations & Theses, : 2019,
面頁冊數:	62 p.
附註:	Source: Masters Abstracts International, Volume: 80-12.
Contained By:	Masters Abstracts International80-12.
標題:	Molecular biology. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=13812190
ISBN:	9781392286685

A New Oncogenic Function of the Glycolytic Enzyme Lactate Dehydrogenase-A in Small Cell Lung Cancer.
Gramyk, Tobin.

A New Oncogenic Function of the Glycolytic Enzyme Lactate Dehydrogenase-A in Small Cell Lung Cancer. - Ann Arbor : ProQuest Dissertations & Theses, 2019 - 62 p.

Source: Masters Abstracts International, Volume: 80-12.

Thesis (M.S.)--Boston University, 2019.

This item must not be sold to any third party vendors.

Small Cell Lung Cancer (SCLC) is an epithelial cancer that has, until recent years, been labeled a recalcitrant tumor type. Since its discovery and classification, there has been very little research to understand and treat SCLC. Conventional methods of treatment for SCLC include chemotherapeutics have been used with little long-term success. Following initial treatment, the cancer appears to be fully wiped out, however seemingly without fail the cancer reemerges with acquired drug resistance and the capability to rapidly metastasize, leading to a five-year survival rate of less than 10%. While there have been continuous improvements in the field of cancer therapeutics, combining chemotherapeutics and immunotherapy, there has been no targeted clinical therapy for SCLC. Recent studies have suggested that an acidic tumor microenvironment is highly important for the progression of other cancers. LDHA generates lactate from pyruvate, leading to a more acidic environment, which indicates LDHA may be a viable target for cancer therapeutics. CRISPR-cas9 gene editing and mouse SCLC cell lines were used to study lactate concentration and cell vitality. After analysis of several different SCLC tumors, larger tumors had both a higher metastatic capability and higher concentrations of lactate, indicating that LDHA was more highly active in these tumors. CRISPR-cas9 knockout targeting of LDHA decreased SCLC colony formation and cellular growth in vitro, leading to the conclusion that LDHA may play a vital role in the future as a potential therapeutic target for the treatment of SCLC.

ISBN: 9781392286685Subjects--Topical Terms:

517296
Molecular biology.

A New Oncogenic Function of the Glycolytic Enzyme Lactate Dehydrogenase-A in Small Cell Lung Cancer.
LDR:02683nmm a2200337 4500 001 2208830
005 20191025102424.5
008 201008s2019 ||||||||||||||||| ||eng d
020 $a 9781392286685
035 $a (MiAaPQ)AAI13812190
035 $a (MiAaPQ)bu:14397
035 $a AAI13812190
040 $a MiAaPQ $c MiAaPQ
100 1 $a Gramyk, Tobin. $3 3435886
245 1 0 $a A New Oncogenic Function of the Glycolytic Enzyme Lactate Dehydrogenase-A in Small Cell Lung Cancer.
260 1 $a Ann Arbor : $b ProQuest Dissertations & Theses, $c 2019
300 $a 62 p.
500 $a Source: Masters Abstracts International, Volume: 80-12.
500 $a Publisher info.: Dissertation/Thesis.
500 $a Advisor: Trinkaus-Randall, Vickery.
502 $a Thesis (M.S.)--Boston University, 2019.
506 $a This item must not be sold to any third party vendors.
520 $a Small Cell Lung Cancer (SCLC) is an epithelial cancer that has, until recent years, been labeled a recalcitrant tumor type. Since its discovery and classification, there has been very little research to understand and treat SCLC. Conventional methods of treatment for SCLC include chemotherapeutics have been used with little long-term success. Following initial treatment, the cancer appears to be fully wiped out, however seemingly without fail the cancer reemerges with acquired drug resistance and the capability to rapidly metastasize, leading to a five-year survival rate of less than 10%. While there have been continuous improvements in the field of cancer therapeutics, combining chemotherapeutics and immunotherapy, there has been no targeted clinical therapy for SCLC. Recent studies have suggested that an acidic tumor microenvironment is highly important for the progression of other cancers. LDHA generates lactate from pyruvate, leading to a more acidic environment, which indicates LDHA may be a viable target for cancer therapeutics. CRISPR-cas9 gene editing and mouse SCLC cell lines were used to study lactate concentration and cell vitality. After analysis of several different SCLC tumors, larger tumors had both a higher metastatic capability and higher concentrations of lactate, indicating that LDHA was more highly active in these tumors. CRISPR-cas9 knockout targeting of LDHA decreased SCLC colony formation and cellular growth in vitro, leading to the conclusion that LDHA may play a vital role in the future as a potential therapeutic target for the treatment of SCLC.
590 $a School code: 0017.
650 4 $a Molecular biology. $3 517296
650 4 $a Cellular biology. $3 3172791
650 4 $a Biochemistry. $3 518028
690 $a 0307
690 $a 0379
690 $a 0487
710 2 $a Boston University. $b Medical Sciences GMS. $3 2103826
773 0 $t Masters Abstracts International $g 80-12.
790 $a 0017
791 $a M.S.
792 $a 2019
793 $a English
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=13812190